Reporter Yoon-seok Seo, Biospectator
Published in Nature Biotechnology.. ‘APP C16 RNAi’ maintained a decrease in APP for more than 3 months in rat and primate models.. Reduced target genes in the eyes and lungs
Alnylam Pharmaceuticals has published a study on C16 RNAi technology that can be delivered to extra-hepatic tissues, particularly the central nervous system (CNS).
The research team confirmed the decrease in the expression of amyloid precursor protein (APP) in rat and primate (NHP) models by administering a drug that binds APP RNAi to C16 (Conjugation of 2′-O-hexadecyl). APP is a protein involved in the formation of amyloid beta, a causative gene of Alzheimer’s disease (AD). Currently, Allylam is conducting phase 1 clinical trial of APP C16 RNAi ‘APP-ALN’ for early onset AD (EOAD) indication.
C16 RNAi was effectively delivered to the eye and lung tissues in addition to the brain, suppressing the expression of the target gene. In particular, the effect of suppressing the expression of the target gene was maintained for several months, demonstrating the potential as a long-acting RNAi drug.
On the 7th of last month (local time), Allylam published the contents of this research in the international scientific journal ‘Nature Biotechnology’.(Nature Biotechnology, IF 20.37)posted in ‘.
According to the paper, the research team administered SOD1 C16 RNAi intrathecally (IT) to a rat model to determine whether C16 RNAi inhibits the target gene. As a result, SOD1 C16 RNAi was delivered to neurons, astrocytes, and microglia of the rat model brain, and at the highest dose of 0.9 mg, SOD1 mRNA in cerebrospinal fluid (CSF) decreased by more than 75%.
The research team found that when SOD1 C16 RNAi (0.9 mg) was administered as a single dose, the SOD1 mRNA level, which decreased by more than 50%, was maintained for regarding 3 months, and when administered monthly for 4.5 months, the SOD1 mRNA level continued to decrease by more than 50%.
Allylam confirmed the effectiveness of the APP target C16 RNAi by administering it to a rat model and a primate model. For APP, the research team first administered 60 mg of APP C16 RNAi to the NHP and confirmed the result of up to 70% and 80% reduction in APP mRNA expression in the spinal cord and brain, respectively, 3 months later. There was no RNAi effect in the kidney or liver for 3 months.
This reduction in APP continued for several months. As a result of analyzing soluble APP (sAPPα, β) as biomarkers in cerebrospinal fluid, the research team confirmed that a decrease of 75% or more was maintained for 2.5 months, and a decrease of 50% or more was maintained for regarding 4.5 months. In addition, as a result of microscopic analysis of tissues such as brain, spinal cord, and ganglia at 3, 6, and 9 months of drug administration, no abnormal findings were observed.
The research team performed intraventricular administration of APP C16 RNAi (ICV) in CVN (Tg-hAPPSwDI/mNos2-/-) AD model mice and following 9 months, decreased Aβ40 deposit and improved behavioral deficit. showed results.
In addition, in the CVN mouse model 9 months following administration of APP C16 RNAi, Iba1 (ionized calcium-binding adapter molecule 1), an inflammatory marker increased by neurodegeneration, significantly decreased (p
Allylam confirmed that C16 RNAi was effectively delivered to the eyes and lungs, suppressing target gene expression. First, the research team administered transthyretin (TTR) C16 RNAi in doses of 3 μg, 30 μg, 100 μg, and 300 μg intravitreal IVT in primates (NHP). As a result, TTR protein decreased by 75% compared to the control group at all doses up to 28 days following administration of TTR C16 RNAi, and following 168 days of administration, TTR protein decreased by regarding 95% or more at 100 μg and 300 μg doses. On the other hand, when TTR RNAi without C16 was administered, there was no reduction effect compared to the control group.
In the mouse model administered intranasally with SOD1 C16 RNAi, the drug was effectively delivered to lung tissues such as bronchioles and alveoli, and SOD1 expression was significantly reduced. SOD1 levels decreased below 50% for 2 months following administration of SOD1 C16 RNAi at a dose of 10 mg/kg and maintained.
“Central nervous system (CNS) diseases are the most difficult to treat,” said Kevin Fitzgerald, CSO, Alaylam. The results are encouraging,” he said. “The CNS delivery platform works for a long time and can be applied as an intrathecal administration method that reduces the number of administrations,” he said. ), we expect to be able to verify the data.”
Meanwhile, Alylam is conducting phase 1 clinical trial of APP C16 RNAi ‘ALN-APP’ with Regeneron as an indication for EOAD. EOAD refers to Alzheimer’s disease whose symptoms begin before the age of 65 and accounts for 4-6% of all Alzheimer’s diseases.
In particular, Alaylam expects that ALN-APP, which targets APP, can be applied to various brain diseases related to APP in addition to AD. This is because most of the drugs currently under development, such as Biogen’s ‘Aduhelm’, target amyloid beta (Aβ), which is formed by cleavage of APP.
▲(Above) C16 RNAi brain neuron transmission and target gene suppression effect (Bottom) Improvement of movement abnormality following administration of APP C16 RNAi in CVN AD model (refer to Allailam data)